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As demonstrated in animal models, mercury 
affects immune function in a complex man-
ner that depends on both the species of Hg 
used and the genetic background against which 
exposure takes place. In genetically susceptible 
mouse strains, inorganic Hg (iHg) and organic 
Hg species induce auto  immunity, resulting in a 
lupus  like condition (Havarinasab and Hultman 
2005). Coexposure to the antigenic stimulus 
lipo  poly  saccharide (LPS), a potent activator 
of the innate immune system, can shift sus-
ceptibility to the immuno  toxic effects of iHg 
such that non  susceptible mouse strains become 
susceptible and susceptible strains experience 
an exacerbation of iHg-induced auto  immune 
disease (Abedi-Valugerdi et al. 2005).
Mouse models of Hg-induced auto-
immune disease suggest that cytokine regula-
tion is an important determinant in terms of 
pathophysiologic outcome (Bagenstose et al. 
1999; Haggqvist and Hultman 2005; Hu et al. 
1999). Particular attention has been paid to the 
balance of cytokines produced by the T-helper 
TH1 and TH2 subsets, and dys  regulation of 
cytokine release is involved in driving responses 
of auto  reactive T cells toward the development 
of auto  immunity (Bagenstose et al. 1998; 
Haggqvist and Hultman 2003).
Humans may also be susceptible to the 
immunotoxic effects of Hg. Hg exposure has 
been associated with increased risk of lupus and 
greater severity of scleroderma (Arnett et al. 
1996; Cooper et al. 2004). Environmental and 
occupational exposures to Hg compounds are 
correlated with serum levels of auto  antibodies, 
a pathology commonly found in murine 
models of Hg-induced auto  immunity (Alves 
et al. 2006; Silbergeld et al. 2005; Silva et al. 
2004). However, other studies have failed to 
find a correlation between occupational Hg 
exposure and markers of immune dysfunction 
(Barregard et al. 1997; Ellingsen et al. 2000).
Human immune function is highly vari-
able in terms of both response to infection and 
conditions such as auto  immune disease, with 
differences between sexes and among people 
of different genetic backgrounds (Fairweather 
et al. 2008; Hill 2006; Klein 2000). It is plau-
sible that the immuno  toxic response to Hg 
will also be highly variable across people as a 
result of genetic or environmental factors.
The goal of our two-phase study was to 
characterize and quantify the human immune 
response to iHg in vitro, in terms of both the 
magnitude of changes in cytokine release and 
the individual variability observed in cytokine 
release. In choosing the Hg species to use, we 
selected iHg because it has been demon  strated 
to be the most potent inducer of immuno-
toxicity in animal models (Havarinasab and 
Hultman 2005). In addition, methyl  mercury 
is metabolized to and retained in the body as 
iHg (Hg2+) (Suda et al. 1992; Vahter et al. 
1994) and is likely the Hg species that even-
tually acts upon immune cells after exposure 
to methyl  mercury (Havarinasab et al. 2007). 
In phase 1 of this study, we used a multi  level 
study design in which volunteers (level 1) were 
asked to return for multiple visits (level 2) for 
blood donations so that we could assess both 
between- and within-individual variability 
in cytokine response (level 3). In phase 2, we 
tested the predictive capability of the models 
we developed in phase 1 to characterize the 
immune response to iHg in vitro using periph-
eral blood mononuclear cells (PBMCs) from 
another independently selected group. We also 
collected information about individual blood 
donors in order to characterize the effects of 
these variables on cytokine response in vitro.
Materials and Methods
Tissue culture chemicals and reagents. All 
chemicals were obtained from Sigma-Aldrich 
(St. Louis, MO) unless otherwise noted. 
Phosphate-buffered saline (PBS), penicillin-
streptomycin, and l-glutamine were obtained 
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Ba c k g r o u n d: The human immune response to mercury is not well characterized despite the body 
of evidence that suggests that Hg can modulate immune responses, including the induction of auto-
immune disease in some mouse models. Dysregulation of cytokine signaling appears to play an 
important role in the etiology of Hg-induced autoimmunity in animal models. 
oBjectives: In this study, we systematically investigated the human immune response to Hg 
in vitro in terms of cytokine release. 
Me t h o d s : Human peripheral blood mononuclear cells (PBMCs) were isolated from 20 volunteers 
who donated blood six separate times. PBMCs were cultured with lipopolysaccharide and concentra-
tions of mercuric chloride (HgCl2) up to 200 nM. Seven cytokines representing important pathways 
in physiologic and pathologic immune responses were measured in supernatants. We used multi  level 
models to account for the intrinsic clustering in the cytokine data due to experimental design. 
re s u l t s: We found a consistent increase in the release of the pro  inflammatory cytokines 
interleukin-1β (IL-1β) and tumor necrosis factor-α, and concurrent decrease in release of the anti-
inflammatory cytokines interleukin 1-receptor antagonist (IL-1Ra) and IL-10 in human PBMCs 
treated with sub  cytotoxic concentrations of HgCl2. IL-4, IL-17, and interferon-γ increased in a 
concentration–response manner. These results were replicated in a second, independently recruited 
population of 20 different volunteers. 
co n c l u s i o n s: Low concentrations of HgCl2 affect immune function in human cells by dys-
regulation of cytokine signaling pathways, with the potential to influence diverse health outcomes 
such as susceptibility to infectious disease or risk of auto  immunity.
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from Mediatech (Manassas, VA). RPMI 1640 
and heat-inactivated fetal bovine serum (hiFBS) 
were obtained from Invitrogen (Carlsbad, 
CA). LPS was reconstituted in sterile PBS as a 
400-ng/mL stock solution and frozen at –20°C 
in aliquots; all experiments used freshly thawed 
LPS aliquots from the same batch. All plastics 
used were certified endotoxin-free by the man-
ufacturer. Ficoll-Paque Plus (GE Healthcare, 
Piscataway, NJ) had endotoxin levels of 
< 0.12 endotoxin units (EU)/mL, PBS had 
< 0.005 EU/mL, and culture media (before 
LPS treatment) had < 0.01 EU/mL.
Human subjects. In phase 1, a conve-
nience sample of 20 healthy adult volunteers 
(10 males and 10 females) were recruited 
from the Johns Hopkins Medical Institutions 
community. Volunteers were required to be 
between 18 and 40 years of age. To avoid obvi-
ous sources of variability within the immune 
system, our exclusion criteria included personal 
or immediate family history of auto  immune 
disease, use of steroidal medications (including 
birth control pills), regular use of non  steroidal 
anti  inflammatory drugs (NSAIDs), receipt of 
organ transplant, and pregnancy. Volunteers 
were asked to donate 20 mL of blood and 
to answer a brief questionnaire about their 
lifestyle and health status. Volunteers were 
asked to repeat this process six times with 
at least 1 month separating each visit [see 
Supplemental Materials, Figure 1, available 
online (doi:10.1289/ehp.0900855.S1)]. All 
volunteers were required to be free of illness (to 
the best of their knowledge) at the time of the 
blood draw. Blood collection for all volunteers 
occurred over a total period of 18 months.
In phase 2, an additional 20 healthy adult 
volunteers (10 males and 10 females) were 
recruited from the same community. These 
volunteers, who met the same inclusion and 
exclusion criteria as those recruited during 
phase 1, were asked to donate blood and 
answer a questionnaire only once.
All volunteers gave written informed con-
sent before participation in this study. All 
activities were conducted in accordance with 
U.S. regulations and were approved by the 
Johns Hopkins Bloomberg School of Public 
Health Committee on Human Research. At 
no point were any volunteers exposed to Hg as 
a result of participation in this study.
Blood collection and cell culture. Venous 
blood (20 mL) was collected by a trained phle-
botomist under aseptic conditions into sodium 
heparin-coated Vacutainer tubes (Becton 
Dickinson, Franklin Lakes, NJ). Whole blood 
was immediately diluted 1:1 with PBS, layered 
over Ficoll, and centrifuged at 1,300 × g for 
30 min to separate PBMCs. Cells were washed 
twice with PBS before being cultured at 106 
cells/mL in RPMI 1640 media supplemented 
with 1.77 mM l-glutamine, 76 µM strepto-
mycin, 44 IU penicillin, 7.44 mM HEPES, 
and 8.9% hiFBS and containing 0, 10, 100, 
or 200 nM mercuric chloride (HgCl2) (with 
PBS as a vehicle). Cells were also separately 
cultured with the same concentrations of 
HgCl2 in the presence of 50 ng/mL LPS. Each 
treatment group was established in triplicate. 
PBMCs were maintained in culture for 48 hr 
at 37°C and 5% CO2. Cells were harvested by 
gentle agitation, followed by centrifugation for 
5 min at 2,000 × g. Cell culture supernatants 
were stored in aliquots at –80°C until analysis.
Cytokine measurement. Cell culture 
super  natants were thawed on ice and ana-
lyzed for cytokine content using the multi-
plex bead-based Bio-Plex suspension array for 
cytokines (Bio-Rad, Hercules, CA) accord-
ing to the manufacturer’s instructions. The 
following seven cytokines were measured in 
all samples: interleukin-1β (IL-1β; detec-
tion range, 0.6–2,527 pg/mL), IL-1 recep-
tor antagonist (IL-1Ra; 5.5–22,701 pg/mL), 
IL-4 (0.1–720 pg/mL), IL-10 (0.9–1,808   
pg/mL),  IL-17  (3.3–6,985  pg/mL), 
interferon-γ (IFN-γ; 6.4–20,882 pg/mL), and 
tumor necrosis factor-α (TNF-α; 1.6–55,716 
pg/mL). For three subjects, we compared 
cytokine meas  urements for TNF-α obtained 
by the multi  plex assay with measurements 
obtained using an enzyme-linked immuno-
sorbent assay (Quantikine, R&D Systems, 
Minneapolis, MN) to validate the multi  plex 
assay (correlation between assay measure-
ments: R2 = 0.966; data not shown).
Statistical analyses. We first plotted and 
examined data on a natural scale and then 
compared median cytokine concentrations for 
each Hg treatment group. The distribution of 
cytokine concentrations for each Hg treatment 
group was examined by calculating the inter-
quartile range (IQR) of all observed responses. 
Because cytokine data are strongly right-skewed, 
the data were log-transformed using the natural 
logarithm. We used STATA10 software (ver-
sion 10IC; StataCorp, College Station, TX) and 
R (version 2.8.0; R Foundation for Statistical 
Computing 2008) to generate graphs. 
Two models—a simple linear regression 
(model 1) and a three-level hierarchical lin-
ear regression model with random intercept 
(model 2)—were then fit to the log-trans-
formed data for each cytokine. Models were 
fit using Bayesian posterior inference based 
on Markov chain Monte Carlo simulation. 
We used WinBUGS software (version 1.4; 
MRC Biostatistics Unit, Cambridge, UK) to 
analyze the data, with non  informative prior 
distributions (Crainiceanu et al. 2005; Lunn 
et al. 2000). We used 100,000 iterations to 
estimate model parameters; the first 10,000 
iterations were discarded. Posterior median 
estimates and 95% credibility intervals (CIs) 
are reported for parameters in each model. 
Data from the phase 2 participants were 
modeled (model 3) using a linear mixed-effects 
model with two-level hierarchy for the random 
intercept. Model 3 had two levels instead of 
three because phase 2 volunteers had only one 
visit, whereas phase 1 volunteers had six visits. 
The posterior median estimates of model 3 
were then compared with the estimates for the 
95% CI of model 2 parameters to analyze the 
predictive properties of model 2 for phase 2 
volunteer responses.
Finally, data from the phase 1 and phase 2 
participants were combined and used in an 
exploratory analysis of the effects of both 
subject-level and visit-level characteristics on 
the intercept and slope of the concentration–
response curve for TNF-α (model 6).
Results
Blood donor characteristics. The phase 1 data 
set consisted of complete concentration– 
response data for seven cytokines on 111 sep-
arate visits from 20 volunteers. One volunteer 
moved away after completing only five visits; 
one volunteer began taking birth control pills 
after three visits; and the remaining five visits 
were censored because of laboratory errors. 
Characteristics of all phase 1 and phase 2 par-
ticipants are summarized in Table 1.
LPS enhances HgCl2 modulation of 
cytokine release. The effects of HgCl2 treat-
ment on cytokine release, both in the presence 
and in the absence of LPS, are summarized in 
Table 2 for all visits of all phase 1 volunteers. 
Changes in cytokine concentration were not 
due to non  specific cytotoxic effects of Hg [see 
Supplemental Material, Figure 2 (doi:10.1289/
ehp.0900855.S1)]. We also did not observe any 
changes in cell subpopulations (CD3–CD19+ 
B cells, CD3+CD4+ T cells, CD3+CD8+ 
T cells, CD11b+ monocytes and macrophages) 
as a result of HgCl2 treatment within PBMC 
cultures from a subset of six volunteers [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0900855.S1)].
In the presence of LPS, the IQRs observed 
for each cytokine were large, reflecting the large 
amount of variation seen in cytokine response 
at different visits and among different volun-
teers. As expected for non  stimulated and non-
contaminated cultures, cytokine levels were 
low in the absence of LPS. The magnitude of 
the changes due to HgCl2 treatment observed 
in the presence of LPS was much greater com-
pared with the changes observed in the absence 
of LPS. In this article we focus on the effects of 
HgCl2 treatment on cytokine release from cells 
that have been stimulated with LPS.
Cytokine responses and model selection. We 
explored data on cytokine release in response 
to HgCl2 treatment using several models. To 
ensure that cytokine concentration data are 
normally distributed, we used log-transformed 
data to model effects of HgCl2 on cytokine 
release [see Supplemental Material, Figure 3 
(doi:10.1289/ehp.0900855.S1)].Gardner et al.
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Model 1 is a simple linear regression:
  y = ln([cytokine]) 
  y | µ, ε ~ N(µ, σ2
ε) 
  µ = β0 + β1[HgCl2]  [1]
This model describes the mean cytokine 
response (µ) as a concentration–response 
curve consisting of an intercept β0, which 
describes the baseline cytokine response to 
LPS in the absence of HgCl2, and a slope β1. 
σ2
ε quantifies the observed variability that is 
unexplained by the model. This model does 
not take into account the correlated and hier-
archical nature of the data set.
The variation observed in the intercept 
of the concentration–response curves sug-
gests that a model with a random intercept 
may be more appropriate to describe the 
data set [see Supplemental Material, Figure 3 
(doi:10.1289/ehp.0900855.S1)]. Model 2 is 
a multi  level linear regression model with a 
random intercept:
  yijk = ln([cytokine]) 
  yijk | µijk, εijk ~ N(µijk, σ2
ε) 
 µ ijk = b0ij + β1[HgCl2]ijk 
  b0ij | b0i, σ2
B ~ N(b0i, σ2
B) 
  b0i | β0, σ2
A ~ N(β0, σ2
A)  [2]
This model accounts for the fact that each 
observation, k, is made within a particular 
visit, j, from a particular volunteer, i. This 
model assumes that the observed cytokine 
response for the ith subject at the jth visit, 
yijk, is normally distributed about its mean, 
µijk, with a variance, quantified by σ2
ε, which 
again quantifies the observed variability that is 
unexplained by the model. Model 2 is simi-
lar to model 1 in that the mean cytokine 
response is modeled as a function of an inter-
cept, β0, and a slope, β1, which describe the 
concentration–response curve. The variance 
about β0 has been further apportioned by 
the introduction of a random intercept for 
each visit, b0ij, and each subject, b0i. The ran-
dom intercept for each visit is assumed to be 
normally distributed about the mean sub-
ject intercept, b0i, with variance σ2
B, which 
quantifies the amount of within-individual 
variation observed within a subject i over j 
multiple visits. The mean subject random 
intercepts, b0i, are assumed to be normally 
distributed about the overall mean intercept 
of the data set, β0, with a variance σ2
A, which 
quantifies the amount of between-individual 
variation observed.
Parameter estimates for each model for 
each cytokine are summarized in Table 3. 
Model 2 estimates (derived from phase 1 vol-
unteers) are depicted as solid blue circles in 
Figure 1. Supplemental Material, Figures 3–6 
(doi:10.1289/ehp.0900855.S1), show close 
agreement between the observed cytokine data 
and model 2 predictions for each cytokine. 
Although the median estimates from both mod-
els for β0 and β1 are similar, model 2 estimates 
for β1 tend to be more precise, revealing a nega-
tive slope for IL-10 and IL-1Ra that is other-
wise obscured. The estimates for σ2
ε are notably 
smaller for model 2 compared with model 1, 
suggesting that model 2 describes a larger por-
tion of the variability in cytokine response.
HgCl2 treatment significantly increased 
the release of the pro  inflammatory cyto-
kines TNF-α and IL-1β in a concentration–
response manner, indicated by a positive 
value for the slope β1. HgCl2 treatment also 
caused a significant reduction in IL-1Ra and 
IL-10 release. We consistently observed each 
of these effects of HgCl2 on cytokine release 
both among subjects and within subjects over 
Table 1. Population characteristics.
Variable Phase 1 volunteersa Phase 2 volunteersb
Subject-level variables
Age (years)
Mean ± SD 28.4 ± 4.99 27.7 ± 4.7
Range 22–39 22–39
Sex [no. (%)]
Male 10 (50) 10 (50)
Female 10 (50) 10 (50)
Ethnicity [no. (%)]
White 11 (55) 15 (75)
Black 4 (20) 2 (10)
Asian American 5 (25) 3 (15)
Extended family history of autoimmune disease [no. (%)]
Yes 6 (30) 6 (30)
No 14 (70) 14 (70)
Vaccinated within 1 year [no. (%)]
Yes 9 (45) 3 (15)
No 11 (55) 17 (85)
Smoking habits [no. (%)]
Some days 1 (5) 3 (15)
Not at all 19 (95) 17 (85)
No. of alcoholic beverages/week
Mean ± SD 3.0 ± 3.5 3.7 ± 2.9
Range 0–15 0–10
No. of dental fillings
Mean ± SD 2.8 ± 3.9 1.7 ± 2.4
Range 0–12 0–8
Visit-level variables
Dental work in past month [no. (%)]
Yes 11 (9.9) 1 (5)
No 100 (90.1) 19 (95)
Total fish consumption in past month (oz)
Mean ± SD 21.7 ± 22.8 24.2 ± 17.8
Range 0–134 0–60
Predatory fish consumption in past month (oz)
Mean ± SD 8.2 ± 12.4 10.7 ± 15.3
Range 0–90 0–56
Nonpredatory fish consumption in past month (oz)
Mean ± SD 13.1 ± 15.8 13.6 ± 10.7
Range 0–84 0–32
Date of visit [no. (%)]
April–September 65 (59) 12 (60)
October–March 46 (41) 8 (40)
Used prescription medicines within 1 month [no. (%)]
Yes 26 (23.4) 4 (20)
No 85 (76.6) 16 (80)
Used NSAIDs within 1 month [no. (%)]
Yes 38 (34.2) 2 (10)
No 73 (65.8) 18 (90)
Used allergy medicines within 1 month [no. (%)]
Yes 10 (9.0) 1 (5)
No 101 (91.0) 19 (95)
Reported cold or flu within 1 month [no. (%)]
Yes 28 (25.3) 9 (45)
No 83 (74.7) 11 (55)
Reported asthma or allergy within 1 month [no. (%)]
Yes 14 (12.6) 3 (15)
No 97 (87.4) 17 (85)
aPhase 1 volunteers (i = 20) were asked to donate blood six times for a total of 111 visits (after dropout and laboratory 
errors). bPhase 2 volunteers (i = 20) were asked to donate blood at a single visit.Mercury induces unopposed inflammation in human PBMCs
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the course of six visits. In addition to affect-
ing the balance of pro  inflammatory and anti-
inflammatory cytokines, HgCl2 also caused a 
significant increase in IFN-γ, IL-4, and IL-17.
To compare the slopes of the concentra-
tion–response curves between the cyto  kines, 
we calculated the coefficient of varia  tion (CV) 
for each cytokine. The CV measures the noise 
in the data compared with the signal by divid-
ing the SD by the mean for each β1 value. 
TNF-α has the lowest CV value (3%), indi-
cating that TNF-α showed the largest and 
most consistent changes in response to HgCl2 
treatment compared with the other cyto  kines 
(IL-4, 6%; IFN-γ, 8%; IL-1Ra, 12%; IL-1β, 
15%; IL-10, 18%; IL-17, 33%).
Estimates for the between-subject varia-
tion, σ2
A, and the within-subject variation, 
σ2
B, are also shown in Table 3. σ2
B accounts 
for a relatively large proportion (> 90% of 
the overall variation for IL-1β, IL-1Ra, IL-4, 
and TNF-α) of the overall variation in the 
data set described by σ2
ε in model 1. σ2
A is 
not precisely estimated from these data for 
any cytokine, suggesting that a larger sample 
size would have been necessary. We simu-
lated a larger data set with similar effect size 
and variance to estimate the necessary sample 
size. Recruiting 45 volunteers with six visits 
each would be adequate to precisely estimate 
σ2
A, although recruiting 50 volunteers with 
three visits each would be a more efficient 
approach to attain the necessary power [see 
Supplemental Material, Figure 7 (doi:10.1289/
ehp.0900855.S1)].
Comparison of phase 1 and phase 2 model 
parameters. To validate the predictive capabil-
ity of these models, we cultured PBMCs from 
20 new subjects (phase 2). After the same 
in vitro treatments with HgCl2 and LPS as 
used in phase 1, we meas  ured cytokine release 
for the same seven cytokines. 
The log-transformed cytokine response 
data (k) were fit with model 3:
  yik = ln([cytokine]) 
  yik | µik, εik ~ N(µik, σ2
ε) 
 µ ik = b0i + β1[HgCl2]ik 
  b0i | β0, σ2
B0 ~ N(β0, σ2
B0).  [3]
We compared median estimates and 
95% CIs for β0 and β1 obtained from 
model 3 using data from 20 phase 2 subjects 
with estimates obtained for each cytokine by 
fitting data from the 20 phase 1 subjects with 
model 2 (Figure 1). We hypothesized that 
median estimates from phase 2 would fall 
within the 95% CI for each model parameter 
predicted based on phase 1 data. Overall, the 
phase 1 model accurately predicts the mag-
nitude and direction of the slope β1 of the 
  concentration–response curve for each 
cytokine, along with accurately predicting the 
range of the intercept β0.
Multilevel mixed effects models provide 
a natural decomposition of observed variance 
into within- and between-subject variance 
and noise variance. A measure of the propor-
tion of total variance in model 2 explained by 
within- and between-subject variation is Rb0:
 R b0 = (σ2
A + σ2
B)/(σ2
A + σ2
B + σ2
ε).  [4]
For model 3, Rb0 is somewhat simpler, 
represented as the proportion of variance 
explained by the random intercept compared 
with the total variance:
  Rb0 = σ2
B0/(σ2
B0 + σ2
ε).  [5]
The Rb0 statistic computed for model 3 was 
also accurately predicted by model 2, based 
on data from phase 1 subjects. Estimates for 
Rb0 for models 2 and 3 are shown in Figure 1.
Subject-specific characteristics may con-
tribute to the variation observed in cytokine 
response. Although our sample size is too 
small to generate an in-depth, multi  variate 
exploration of the effects of subject- and visit-
specific characteristics on cytokine response, 
we were able to use the questionnaire data col-
lected on health and lifestyle in a hypothesis-
generating, exploratory analysis of the effects 
of these characteristics on TNF-α release. We 
combined the data sets for both phase 1 and 
phase 2 participants for this analysis:
  yijk = ln([cytokine]) 
  yijk | µijk, εijk ~ N(µijk, σ2
ε) 
 µ ijk = b0ij + β1[HgCl2]ijk + β2(varijk) + 
  β3(varijk × [HgCl2]ijk) 
  b0ij | b0i, σ2
B ~ N(b0i, σ2
B) 
  b0i | β0, σ2
A ~ N(β0, σ2
A).  [6]
Table 3. Model parameter estimates (95% CIs).
Cytokine Model β0 β1 σ2
A σ2
B σ2ε
IL-1β 1  6.35 (6.29–6.41) 8.68 × 10–4 (3.17 × 10–4 to 14.3 × 10–4) — — 0.495 (0.453–0.542)
2  6.41 (4.61–8.27) 8.97 × 10–4 (6.38 × 10–4 to 11.5 × 10–4) 0.0898 (0.0018–43.1) 0.361 (0.267–0.505) 0.109 (0.0990–0.119)
IL-1Ra 1 6.31 (6.24–6.38) 5.39 × 10–4 (–11.5 × 10–4 to 6.47 × 10–4) — — 0.781 (0.723–0.845)
2 6.32 (4.94–7.66) –5.25 × 10–4 (–6.54 × 10–4 to –3.99 × 10–4) 0.0413 (9.64 × 10–4 to 22.74) 0.742 (0.570–0.987) 0.0347 (0.0320–0.0378)
IL-4 1 0.738 (0.704–0.773) 6.09 × 10–4 (3.80 × 10–4 to 9.99 × 10–4) — — 0.204 (0.189–0.221)
2 0.742 (–0.123 to 1.594) 7.05 × 10–4 (6.20 × 10–4 to 7.88 × 10–4) 0.0185 (8.20 × 10–4 to 9.25) 0.187 (0.144–0.250) 0.0153 (0.0141–0.0166)
IL-10 1 4.97 (4.90–5.04) –3.86 × 10–4 (–10.2 × 10–4 to 2.44 × 10–4) — — 0.850 (0.787–0.920)
2 4.97 (3.86–6.07) –3.33 × 10–4 (–4.50 × 10–4 to –2.18 × 10–4) 0.0255 (7.86 × 10–4 to 14.9) 0.842 (0.647–1.12) 0.0291 (0.0269–0.0317)
IL-17 1 2.45 (2.39–2.52) 4.01 × 10–4 (–2.04 × 10–4 to 10.0 × 10–4) — — 0.773 (0.716–0.837)
2 2.45 (1.71–3.17) 4.27 × 10–4 (1.51 × 10–4 to 6.98 × 10–4) 0.0122 (6.46 × 10–4 to 6.49) 0.623 (0.477–0.834) 0.160 (0.148–0.174)
IFN-γ 1 5.45 (5.40–5.49) 6.31 × 10–4 (2.22 × 10–4 to 10.4 × 10–4) — — 0.375 (0.347–0.405)
2 5.42 (2.04–8.81) 6.56 × 10–4 (5.53 × 10–4 to 7.61 × 10–4) 0.329 (0.0253–131.32) 0.276 (0.214–0.367) 0.0240 (0.0221–0.0260)
TNF-α 1 5.67 (5.61–5.72) 20.0 × 10–4 (15.5 × 10–4 to 25.0 × 10–4) — — 0.501 (0.464–0.541)
2 5.66 (4.13–7.21) 20.0 × 10–4 (18.8 × 10–4 to 21.1 × 10–4) 0.0592 (0.0014–28.9) 0.459 (0.355–0.608) 0.0308 (0.0285–0.0334)
Model estimates are derived from log-transformed data from phase 1 volunteers for cells treated with LPS. Model 1 is a simple linear regression, and model 2 is a three-level hier-
archical linear mixed-effects model. 
Table 2. Cytokine response summary.
HgCl2 treatment
Cytokine LPS 0 nM 200 nM
IL-1β Negative 2.0 (0.95–4.5)  2.7 (0.9–5.3)
Positive 525.8 (372.7–851.9) 617.1 (418.8–1255.3)
IL-1Ra Negative 21.4 (10.9–58.2) 24.8 (12.8–63.3)
Positive 527.3 (270.3–985.0) 473.6 (266.9–880.5)
IL-4 Negative 0.3 (0.1–0.4) 0.3 (0.1–0.4)
Positive 2.0 (1.6–2.8) 2.3 (1.8–3.3)
IL-10 Negative 1.6 (1.1–2.5) 1.3 (0.9–2.2)
Positive 143.6 (85.4–266.4) 130.8 (75.0–277.4)
IL-17 Negative 8.8 (4.5–11.9) 8.1 (4.1–11.2)
Positive 14.5 (11.1–18.2) 14.8 (11.2–19.8)
IFN-γ Negative 14.5 (7.0–31.2) 14.1 (7.1–30.9)
Positive 216.5 (152.3–363.7) 248.1 (174.8–381.8)
TNF-α Negative 3.7 (2.6–5.0) 4.5 (2.8–6.8)
Positive 338.9 (181.3–471.4) 456 (258.6–710.7)
Values shown are median (IQR) in pg/mL and include all visits from all phase 1 volunteers. Gardner et al.
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In addition to the multi  level random inter-
cept, model 6 contains the terms “[HgCl2]ijk” 
and “varijk” as explanatory variables. “Var” rep-
resents each variable (e.g., sex) that was tested 
individually in the model. Potential inter  action 
between each variable and HgCl2 treatment 
was modeled with the term varijk × [HgCl2]ijk. 
Posterior distributions were computed for the 
intercept (β0 + β2) and slope (β1 + β3) for 
each subpopulation examined (e.g., males and 
females). These estimates are compared with 
the estimates for the intercept (β0) and slope 
(β1) of the TNF-α concentration–response 
curve derived from model 2 using data from 
all 40 subjects (Figure 2).
None of the variables tested had a statisti-
cally significant impact on the estimate for the 
intercept. Ethnicity had the largest effect on the 
intercept, with non  white participants showing 
a tendency toward a higher value. Having an 
allergic reaction or asthma attack had the larg-
est impact on the estimate for β1. Being female 
or non  white, consuming more than two alco-
holic beverages per week, having an extended 
family member with auto  immune disease, 
being vaccinated within 1 year of the visit, and 
having no dental fillings made of Hg amalgam 
all also increased the estimate of β1 compared 
with model 2 estimates. These results suggest 
that individual-level characteristics, as well as 
visit-level characteristics, may affect the inter-
cept and slope of the concentration–response 
curve for TNF-α.
Discussion
In this study we found that low, physi-
ologically relevant concentrations of iHg 
up-regulate the release of pro  inflammatory 
TNF-α and IL-1β and down-regulate anti-
inflammatory IL-10 and IL-1Ra release in 
a concentration–response fashion in LPS-
stimulated human PBMCs in vitro. The high-
est HgCl2 concentration we used (200 nM) 
corresponds to a blood Hg level of 37 µg/L, 
which has been observed in populations 
exposed to Hg occupationally or through con-
sumption of methylmercury-contaminated fish 
and is well within the range of U.S. exposures 
(Crompton et al. 2002; Hightower and Moore 
2003). LPS used to stimulate the PBMCs in 
this system interacts with the Toll-like recep-
tor 4 (TLR4) receptor complex on monocytes 
and macro  phages. Exposure to infectious 
agents that stimulate TLR4 signaling is known 
to modulate the risk of auto  immune disease 
in humans (Cooke et al. 2008) and is criti-
cal to some animal models of auto  immunity 
(Frisancho-Kiss et al. 2007). A growing litera-
ture indicates that Hg can interact with infec-
tious disease stimuli to increase inflammation 
and exacerbate auto  immune disease (Abedi-
Valugerdi et al. 2005; Silbergeld et al. 2005). 
Here we have provided further evidence that 
Hg can interact with infectious disease stimuli, 
Figure 1. Model estimates [median (95% CI)] derived from phase 1 volunteers predict the response to LPS 
and HgCl2 in phase 2 volunteers. Model 2 estimates for concentration–response curves for each of the seven 
different cytokines derived from the log-transformed data from 111 visits of the 20 phase 1 volunteers are 
compared with model 3 estimates derived from the single visit of the 20 phase 2 volunteers. β0 is the estimate 
for the intercept of the HgCl2 concentration–response curve; β1 is the estimate for slope (log change in pg/mL 
of cytokine per 1-nM increase in HgCl2); and Rb0 is the proportion of variation in the data set that is explained 
by variation in the baseline response to LPS. The vertical dashed lines for β0 and β1 indicate zero.
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Figure 2. Subject- and visit-specific variables may affect response to LPS and HgCl2. AI, autoimmune. 
Total data for TNF-α release for all subjects (i = 40) and all visits (j = 131) were evaluated with model 6. 
The effect of each covariate was tested on both the intercept (β0) and the slope (β1) using concentration–
response data from the specified subpopulations (see Table 1 for covariate descriptions). The estimated 
median and 95% CI for each model parameter were compared with the median model estimates from a 
model with no covariates (model 2), represented by the dashed vertical lines. 
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in this case modulating the cytokine response 
to LPS.
Regulation of pro  inflammatory cytokines 
is tightly controlled in physiologically appro-
priate immune responses. Induction of anti-
inflammatory responses generally occurs soon 
after or concurrently with pro  inflammatory 
cytokine induction (Arend 2002). Imbalance 
in pro- and anti  inflammatory cytokine pro-
duction has been implicated in the etiology of 
many diseases, including autoimmune diseases 
and atherosclerosis (Apostolakis et al. 2008; 
Suh and Kim 2008). Our model predicts an 
increase of 119 pg/mL IL-1β and 141 pg/mL 
TNF-α over a 200 nM increase of HgCl2, 
which well reflects the observed increases in 
our study. Changes of this magnitude are bio-
logically significant, because lupus patients 
have elevated serum TNF-α and IL-1β 
concentrations of a similar magnitude com-
pared with controls (Sabry et al. 2006; Suh 
and Kim 2008). The Hg-induced increases in 
pro  inflammatory cytokine release are unop-
posed by the physiologically appropriate anti-
inflammatory response; in fact, IL-1Ra and 
IL-10 release are suppressed by Hg treatment.
Most rodent studies of Hg-induced auto-
immunity have focused on the influence of TH1 
and TH2 cell populations (Hu et al. 1999). 
Here we show evidence that in humans TH1 
and TH2 subsets may also be affected by Hg 
because both IL-4 and IFN-γ are slightly up-
regulated in response to iHg treatment in acti-
vated PBMCs. Because other cell populations 
can produce these cytokines—and we observe 
both up-regulation of IL-4 and down-regula-
tion of IL-10, which can both be produced by 
TH2 cells—further study is necessary to ascer-
tain the cell populations affected by iHg. IL-17 
is also up-regulated in response to Hg treat-
ment. IL-17 is produced by CD4+ TH17 cells, 
which play a role in the etiology and pathology 
of autoimmune disorders (Wilson et al. 2007).
In the data presented here, the variabil-
ity in the slope of the iHg concentration–re-
sponse curve is relatively small compared with 
the variability observed in baseline response 
to LPS, indicating that the baseline response 
determined the relative cytokine release in 
the presence of iHg (i.e., partici  pants who 
had a strong inflammatory response to LPS 
alone had much higher absolute levels of 
pro  inflammatory cytokines after Hg expo-
sure in vitro). The apparent influence of vari-
ability observed in the baseline inflammatory 
response could have implications for varia-
tions in in vivo susceptibility to the immu-
notoxic effects of Hg. Those individuals who 
mount a more intense inflammatory response 
in the presence of an infectious stimulus may 
be at greater risk of pathology due to increased 
inflammation as a result of Hg exposure. We 
speculate that individuals with genetic suscepti-
bility to diseases charac  terized by dys  regulation 
of inflammation may be at particular risk of 
pathophysiologic consequences as a result of 
Hg exposure. An emerging emphasis on the 
inflammatory basis of cardio  vascular disease 
is particularly intriguing (Apostolakis et al. 
2008; Boyle 2005), given that a significant 
association has been observed between elevated 
methyl  mercury exposures resulting from fish 
consumption and increased risk for myocardial 
infarction despite the cardio  protective effects 
of fish consumption (Guallar et al. 2002). Our 
results further support the need to investigate 
interactions among Hg exposure, inflamma-
tion, and chronic disease risk.
Human PBMCs are receiving increasing 
attention, especially in the area of regulatory 
toxicology, and are a popular choice as a model 
system in immuno  toxicology (Chaudhary 
et al. 2004; Giese et al. 2006; Hoffmann et al. 
2005). The use of PBMCs fulfills the vision 
recently set forth by the U.S. National Research 
Council for the future of toxicology testing, 
in which human cells are studied in vitro 
for xeno  biotic effects on signaling pathways 
(National Research Council 2007). However, 
the large amount of variability that is observed 
in response to xeno  biotics in PBMCs taken 
from different individuals presents an analyti-
cal challenge when interpreting data from this 
model system. The variability observed in vitro 
is not an artifact of the model but reflects the 
highly variable nature of the human immune 
response (Coury et al. 2008; Garner-Spitzer 
et al. 2008; Love et al. 2008). As such, the 
use of human PBMCs in culture represents an 
opportunity to study and quantify the range of 
human responses to xeno  biotics. This informa-
tion has the potential to be of value during the 
process of risk assessment because uncertainty 
factors of 3 or 10 are normally applied in the 
process of defining acceptable exposure levels 
in order to account for variability in human 
responses (National Research Council 1983). 
Using a quantitative statistical method such 
as we have used in this study could allow for 
informative and appropriate factors to be 
applied in this process, based on the level of 
variability observed within the assay end points 
in a variety of model systems.
Conclusions
Low concentrations of iHg affect immune 
function in human cells by dysregulation of 
cytokine signaling pathways. Given the inte-
gral nature of cytokine signaling in all aspects 
of immune function, these effects may have 
the potential to influence diverse health out-
comes such as susceptibility to infectious dis-
ease or risk of autoimmunity. The present 
study demonstrates the importance of consid-
ering the immune system as a specific target 
of Hg toxicity and thus indicates the need for 
continued study of the role of Hg exposure in 
infections and chronic disease. 
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